Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savolitinib in Gastric Cancer and Esophagogastric Junction Adenocarcinoma With MET Amplifications
NCT04923932Phase 2Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Jul 2021
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of savolitinib in gastric cancer (GC), esophagogastric junction adenocarcinoma (GEJA), sponsored by Hutchison MediPharma (HMP). Started Jul 2021; status: completed.
02
Drugs
savolitinib
03
Conditions
gastric cancer (GC)esophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT04923932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04923932.